

Advisory Board Agenda

Title: Advisory Board to Seek Advice on the Evolving Treatment Paradigms in Front-Line Metastatic NSCLC – Role of Antiangiogenic Therapies

Date and Location: September 10, 2015 – Smallville Hotel, Beirut – Lebanon

Participants:

External: 13 Experts - including Chair

Roche: Medical Manager, Country Manager.

Time	Topic
18:00 – 18:05	Roche Welcome Medical Manager
18:05 – 18:15	Chair's introduction and meeting objectives Medical Manager
18:15- 19:00	Session 1
18:15- 18:45	Systemic Therapy for Advanced Disease Prof. de Marinis Feedback from all advisors
18:45- 19:00	Mechanisms of angiogenesis and NSCLC Prof. de Marinis Feedback from all advisors
19:00 – 19:30	Role of Antiangiogenic Therapies in the Treatment of Advanced NSCLC Prof. de Marinis Feedback from all advisors
19: 30 – 19:45	Advances in the Treatment of EGFR Mutation Positive NSCLC Prof. de Marinis Feedback from all advisors
19: 45 – 20:00	Optimal Clinical Application of Maintenance Therapy Feedback from all advisors
20:00 – 20:15	Directions in the Optimal Treatment of Patients With Mesothelioma Feedback from all advisors
20:15 -20:30	Patient Selection and Safety with Antiangiogenic Treatment Feedback from all advisors

Session 2	
20:30- 21:00	Scientific Guidelines and Recommendations for the Treatment of Advanced NSCLC Feedback from all advisors
21:00	Meeting Close Chair and Roche Medical Manager

Meeting Objectives:

- Seek advice on current clinical evidence, expert guidance, and treatment recommendations to choose a front-line systemic therapy and maintenance strategy that is most likely to improve outcomes in patients with advanced non-small-cell lung cancer
- Seek advice on identifying subpopulations of patients with advanced non-small-cell lung cancer most likely to benefit from antiangiogenic based treatment plan
- Seek advice on how to identify and manage treatment-related adverse effects associated with the care of patients with advanced non-small-cell lung cancer